PMID: 11929124Apr 4, 2002Paper

OX40: targeted immunotherapy--implications for tempering autoimmunity and enhancing vaccines

Trends in Immunology
Andrew D Weinberg

Abstract

OX40 (CD134), a membrane-bound member of the tumor-necrosis-factor-receptor superfamily, is expressed primarily on activated CD4+ T cells. Recently, several groups have reduced clinical signs of autoimmunity in animal models by blocking the OX40-OX40-ligand interaction or depleting OX40+ T cells. By contrast, engagement of OX40 in the setting of active immunization has potent adjuvant properties, leading to enhanced cytokine production and increased numbers of antigen-specific memory T cells. These potent adjuvant effects lead to an enhancement of anti-tumor responses. OX40 has several unique features that make it a clinically relevant target. They include: (1) T cells isolated from a site of inflammation that express OX40 are T cells that have been stimulated recentlythrough the T-cell receptor in vivo; (2) OX40 is only expressed on T cells found at the site of inflammation, therefore, targeting this receptor does not interfere with the peripheral T-cell repertoire; and (3) the biological function of OX40 is limited primarily to effector CD4+ T cells, which are a major source of cytokines to induce and maintain ongoing immune responses.

References

Dec 22, 1999·The Journal of Immunology : Official Journal of the American Association of Immunologists·J R MaxwellA T Vella
Jan 19, 2000·The Journal of Experimental Medicine·K MurataK Sugamura
Feb 5, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·A D WeinbergJ Shields
Jul 25, 2000·Journal of the American Society of Nephrology : JASN·Jan AtenJan J Weening
Sep 7, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·I GramagliaM Croft
Nov 9, 2000·European Journal of Immunology·T YoshiokaK Okumura
May 22, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·V MalmströmF Powrie
Aug 2, 2001·Nature Medicine·P Bansal-PakalaM Croft
Nov 21, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·J KjaergaardS Shu
Jun 14, 2003·TheScientificWorldJournal·P Bansal-Pakala, M Croft

❮ Previous
Next ❯

Citations

Dec 5, 2006·Cancer Immunology, Immunotherapy : CII·Andreas Hombach, Hinrich Abken
Jul 8, 2010·Cancer Immunology, Immunotherapy : CII·Juan DubrotIgnacio Melero
Aug 11, 2005·Current Oncology Reports·Christian H PoehleinBernard A Fox
Nov 5, 2002·Current Opinion in Immunology·Fabienne Mackay, Susan L Kalled
Jul 10, 2002·Trends in Immunology·Hinrich AbkenBarbara Seliger
Apr 23, 2003·Current Opinion in Rheumatology·Joseph C ShanahanRobert H Carter
Sep 9, 2005·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Bruce R Blazar, William J Murphy
Jan 12, 2012·Journal of Biomedicine & Biotechnology·Ricardo F AntunesIngrid E Dumitriu
May 2, 2003·Proceedings of the National Academy of Sciences of the United States of America·Susumu NakaeYoichiro Iwakura
Apr 7, 2015·Expert Review of Clinical Pharmacology·Barbara ZarzyckaEsther Lutgens
Apr 17, 2004·Kidney International·Mohammed Javeed I Ansari, Mohamed H Sayegh
Oct 25, 2011·Immunological Reviews·Andrew D WeinbergBrendan D Curti
Dec 7, 2005·Biochemical and Biophysical Research Communications·Massimiliano RiaJacob Lagercrantz
Dec 31, 2003·Cellular Immunology·Jorgen KjaergaardSuyu Shu
May 8, 2004·Seminars in Immunology·Edward M BertramTania H Watts
Jul 11, 2008·Immunological Reviews·Todd M BruskoJeffrey A Bluestone
Aug 13, 2009·European Journal of Immunology·William L RedmondAndrew D Weinberg
Oct 19, 2010·The American Journal of Pathology·Zili ZhangJames T Rosenbaum
Dec 4, 2004·The Journal of Clinical Investigation·Reiko HoraiYoichiro Iwakura
Dec 14, 2011·Brain, Behavior, and Immunity·Xingqi ZhangJoanne Weinberg
Jul 19, 2008·Chemistry & Biology·Claudia M DollinsBruce A Sullenger
Jan 1, 2013·Journal of Drug Delivery Science and Technology·N H KimO M Merkel
Aug 18, 2004·Trends in Molecular Medicine·Tracy HussellAndrew E Williams
Jan 20, 2011·Annals of Saudi Medicine·Mohamed N FarresNermine M Abd Raboh
Aug 19, 2004·Vaccine·Selman A AliRobert C Rees
Dec 23, 2006·Journal of Leukocyte Biology·Andrew J LepistoRobert L Hendricks
Apr 22, 2006·Arteriosclerosis, Thrombosis, and Vascular Biology·Mitsuaki IsobeJun-Ichi Suzuki
Oct 26, 2006·Journal of Immunotherapy·Andrew D WeinbergWalter J Urba
Apr 10, 2008·Journal of Hypertension·Yoichi MashimoAkira Hata
Mar 17, 2006·European Journal of Immunology·Cortny A HuddlestonDavid C Parker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.